April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
A Novel Strategy To Develop Therapeutic Approaches To Prevent Proliferative Vitreoretinopathy
Steven Pennock; Marc-Andre Rheaume; Shizuo Mukai; Joanne A. Matsubara; Jing Cui; David Maberley; Patrick Ma; Arif Samad; R.J. van Geest; Andrius Kazlauskas
Author Affiliations & Notes
  • Steven Pennock
    Schepens Eye Research Institute, Boston, Massachusetts
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • Marc-Andre Rheaume
    Retina Service, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts
  • Shizuo Mukai
    Retina Service, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts
  • Joanne A. Matsubara
    Ophthal & Visual Science, University of British Columbia, Vancouver, British Columbia, Canada
  • Jing Cui
    Ophthal & Visual Science, University of British Columbia, Vancouver, British Columbia, Canada
  • David Maberley
    Ophthal & Visual Science, University of British Columbia, Vancouver, British Columbia, Canada
  • Patrick Ma
    Ophthal & Visual Science, University of British Columbia, Vancouver, British Columbia, Canada
  • Arif Samad
    Department of Ophthalmology and Visual S, Dalhousie University, Halifax, Nova Scotia, Canada
  • R.J. van Geest
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands
  • Andrius Kazlauskas
    Schepens Eye Research Institute, Boston, Massachusetts
    Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Steven Pennock, None; Marc-Andre Rheaume, None; Shizuo Mukai, None; Joanne A. Matsubara, None; Jing Cui, None; David Maberley, None; Patrick Ma, None; Arif Samad, None; R.J. van Geest, None; Andrius Kazlauskas, None
  • Footnotes
    Support  Department of Defense
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4924. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      A Novel Strategy To Develop Therapeutic Approaches To Prevent Proliferative Vitreoretinopathy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      Steven Pennock, Marc-Andre Rheaume, Shizuo Mukai, Joanne A. Matsubara, Jing Cui, David Maberley, Patrick Ma, Arif Samad, R.J. van Geest, Andrius Kazlauskas; A Novel Strategy To Develop Therapeutic Approaches To Prevent Proliferative Vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4924.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Proliferative vitreoretinopathy (PVR) remains an obstacle to successful repair of rhegmatogenous retinal detachments. There is currently no effective prevention or treatment for PVR. Platelet-derived growth factor receptor α (PDGFRα) is associated with formation of PVR in humans, and strongly promotes experimental PVR. Surprisingly, experimental PVR is driven by vitreal growth factors outside of the PDGF family. The purpose of this study was to identify those vitreal growth factors necessary for experimental PVR and establish a potential approach to prevent PVR.

Methods: : Vitreous samples were obtained from experimental rabbits or patients undergoing retinal detachment repair. A panel of 21 growth factors, all of which have been implicated in PVR, were quantified in vitreous using either multiplex assays, or quantitative western immunoblotting. Those growth factors found elevated in PVR vitreous were tested for their ability to promote signaling events and cellular responses intrinsic to PVR. Antibodies and traps that neutralize the candidate growth factors were tested for their ability to prevent experimental PVR.

Results: : Neutralizing a subset of growth factors present in vitreous eliminated its ability to induce PVR-relevant signaling events and cellular responses; these include TGFα, EGF, HGF, TGF-β1, IGF-1, FGF-2, and IL-8. A single vitreal injection of antibodies and traps selective for this set of growth factors prevented PVR. We also subjected human vitreous to a similar neutralization assay. The same panel of 21 growth factors were profiled in patient PVR vitreous. Subsequent testing of their ability to induce PVR-related signaling events and cellular responses accurately identified those that were required for vitreous-induced contraction of primary RPE cells from a patient PVR membrane. The essential growth factors were nearly identical to those found in rabbits.

Conclusions: : A set of growth factors was identified that appears important in PVR formation in the rabbits and in patients. These findings strongly support the idea that vitreal growth factors are a driving force in PVR and constitute realistic therapeutic targets.

Keywords: proliferative vitreoretinopathy • growth factors/growth factor receptors 
© 2011, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept